In short
A new clinical trial is exploring the potential of a vaccine called WT1 mRNA DC to prevent relapse in adults with acute myeloid leukemia (AML). This innovative treatment uses dendritic cells, a type of immune cell, to target a specific protein called Wilms' tumor 1 (WT1) that is often found in leukemia cells. The trial aims to determine if this vaccine can effectively boost the immune system's ability to fight against remaining cancer cells and improve overall survival for AML patients.
At a glance
- Trial Type
- Phase II, multicenter, randomized, open-label
- Main Objective
- Determine efficacy of WT1 mRNA DC vaccination to prevent relapse and prolong overall survival in AML patients
- Target Population
- Adults (≥18 years) with AML at high risk of relapse
- Treatment
- WT1 mRNA-electroporated dendritic cell vaccination
- Administration
- Intradermal injection
- Primary Endpoint
- Overall survival
- Secondary Endpoints
- Relapse-free survival, relapse rate, minimal residual disease, immune responses, quality of life
- Eligibility
- Completed specific chemotherapy regimens, achieved complete remission or CRi, good performance status
- Exclusion Criteria
- Other malignancies, immunosuppressive diseases, use of immunosuppressive drugs, pregnancy
What is WT1 mRNA DC?
WT1 mRNA DC is an innovative vaccine being studied for the treatment of Acute Myeloid Leukemia (AML). This vaccine is a type of cell therapy, which means it uses cells from your own body to fight the disease.
The full name of this treatment is "Wilms' tumor (WT1) antigen-targeted dendritic cell vaccination." Let's break this down:
- Wilms' tumor (WT1): This refers to a specific protein found in many leukemia cells.
- Dendritic cells: These are special immune cells that help your body recognize and fight off harmful substances.
- Vaccination: Unlike traditional vaccines that prevent diseases, this is a therapeutic vaccine designed to treat an existing condition.
Target Condition: Acute Myeloid Leukemia
WT1 mRNA DC is being developed to treat Acute Myeloid Leukemia (AML). AML is a type of blood cancer that affects the bone marrow, where blood cells are made. In AML, abnormal white blood cells grow rapidly, interfering with the production of normal blood cells.
How WT1 mRNA DC Works
The WT1 mRNA DC vaccine works by stimulating your immune system to fight leukemia cells. Here's a simplified explanation of the process:
- Doctors collect some of your monocytes (a type of white blood cell).
- These monocytes are transformed into dendritic cells in a laboratory.
- The dendritic cells are then "loaded" with WT1 mRNA, which contains instructions for making the WT1 protein found on leukemia cells.
- When injected back into your body, these modified dendritic cells help your immune system recognize and attack leukemia cells that have the WT1 protein.
This approach is known as immunotherapy because it uses your own immune system to fight the cancer.
Clinical Trial Details
WT1 mRNA DC is currently being studied in a Phase II clinical trial. This means that while it has shown promise in earlier studies, it is still considered experimental. The main goals of this trial are:
- To see if the vaccine can prevent AML from coming back (relapse) after initial treatment.
- To determine if it can help patients live longer overall.
- To check if it can reduce or eliminate any remaining cancer cells after standard treatment (known as minimal residual disease).
- To study how the vaccine affects patients' immune systems and quality of life.
Eligibility Criteria
Not all AML patients are eligible for this trial. Some key criteria include:
- Being 18 years or older
- Having a high risk of AML relapse
- Having completed standard AML treatment and achieved remission
- Not being eligible for or choosing not to have a stem cell transplant
There are also several factors that might exclude a patient from participating, such as having certain other medical conditions or being pregnant.
Potential Benefits
While the effectiveness of WT1 mRNA DC is still being studied, researchers hope it may offer several benefits:
- Preventing or delaying AML relapse
- Improving overall survival
- Eliminating remaining cancer cells after standard treatment
- Enhancing quality of life for AML patients
Administration and Treatment Duration
WT1 mRNA DC is given as an intradermal injection, which means it's injected just under the skin. The treatment period can last up to 97 days (about 3 months). The exact dosing schedule and amount may vary based on individual patient factors and will be determined by the healthcare team.